(Q34987658)

5 August 2017

1 reference

title

Consensus statement for the management of chronic pelvic pain and endometriosis: proceedings of an expert-panel consensus process (English)

1 reference

5 August 2017

0 references

0 references

1 reference

Brian S Mittman

2

0 references

author name string

Joseph C Gambone

1

1 reference

5 August 2017

Malcolm G Munro

3

1 reference

5 August 2017

Anthony R Scialli

4

1 reference

5 August 2017

Craig A Winkel

5

1 reference

5 August 2017

Chronic Pelvic Pain/Endometriosis Working Group

6

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 November 2002

1 reference

5 August 2017

published in

Fertility and Sterility

1 reference

5 August 2017

volume

78

1 reference

5 August 2017

issue

5

1 reference

5 August 2017

page(s)

961-972

1 reference

Validation of hysterectomy indications and the quality assurance process.

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

Suggestive evidence that pelvic endometriosis is a progressive disease, whereas deeply infiltrating endometriosis is associated with pelvic pain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

Combined hysteroscopic and laparoscopic findings in patients with chronic pelvic pain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

Randomized controlled trial of depot leuprolide in patients with chronic pelvic pain and clinically suspected endometriosis. Pelvic Pain Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

Is endometriosis a disease?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

Endometriosis, 1995--confusion or sense?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

Developing and implementing clinical practice guidelines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

Severe, primary dysmenorrhea treated with naproxen. A prospective, double-blind, crossover investigation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

The Treatment of Endometriosis by Inducing Pseudopregnancy with Ovarian Hormones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

Dysmenorrhea and use of oral contraceptives in adolescent women attending a family planning clinic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

The influence of different combined oral contraceptives on the prevalence and severity of dysmenorrhea

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

Effect of various oral contraceptive combinations on dysmenorrhea

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

Endometriosis 1990. Current treatment approaches

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

Placebo-controlled comparison of hormonal and biochemical effects of danazol and high-dose medroxyprogesterone acetate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis after conservative surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

A randomized, comparative trial of triptorelin depot (D-Trp6-LHRH) and danazol in the treatment of endometriosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

A Comparative Treatment Trial of Endometriosis Using the Gonadotrophin-releasing Hormone Agonist, Nafarelin, and the Synthetic Steroid, Danazol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

Depot leuprolide versus danazol in treatment of women with symptomatic endometriosis. I. Efficacy results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

Depot leuprolide acetate versus danazol for treatment of pelvic endometriosis: changes in vertebral bone mass and serum estradiol and calcitonin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

Nafarelin versus danazol in the treatment of endometriosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

A comparison of nafarelin acetate and danazol in the treatment of endometriosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

An open randomized comparative study of the effect of goserelin depot and danazol in the treatment of endometriosis. Zoladex Endometriosis Study Team

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

Medroxyprogesterone acetate supplementation diminishes the hypoestrogenic side effects of gonadotropin-releasing hormone agonist without changing its efficacy in endometriosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

Effectiveness of tibolone on hypoestrogenic symptoms induced by goserelin treatment in patients with endometriosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

Can hormone replacement therapy be used during medical therapy of endometriosis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

Comparison of the gonadotropin-releasing hormone agonist goserelin acetate alone versus goserelin combined with estrogen-progestogen add-back therapy in the treatment of endometriosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

Goserelin acetate (Zoladex) with or without hormone replacement therapy for the treatment of endometriosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

Prolonged gonadotropin-releasing hormone agonist treatment of symptomatic endometriosis: the role of cyclic sodium etidronate and low-dose norethindrone "add-back" therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

Efficacy and safety of nafarelin in the treatment of endometriosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

Progestins for symptomatic endometriosis: a critical analysis of the evidence.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

Surgical treatment of endometriosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

Effects of 3 month therapy with danazol after laparoscopic surgery for stage III/IV endometriosis: a randomized study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

Low-dose danazol after combined surgical and medical therapy reduces the incidence of pelvic pain in women with moderate and severe endometriosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

Postsurgical medical treatment of advanced endometriosis: Results of a randomized clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

A gonadotrophin-releasing hormone agonist compared with expectant management after conservative surgery for symptomatic endometriosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

Use of nafarelin versus placebo after reductive laparoscopic surgery for endometriosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

Conservative laparoscopic excision of endometriosis by sharp dissection: life table analysis of reoperation and persistent or recurrent disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

Reoperation after laparoscopic treatment of ovarian endometriomas by excision and by fenestration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

Randomized clinical trial of two laparoscopic treatments of endometriomas: cystectomy versus drainage and coagulation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

Laparoscopy versus laparotomy in conservative surgical treatment for severe endometriosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

Surgical treatment of recurrent endometriosis: laparotomy versus laparoscopy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

Laparoscopy versus microsurgery by laparotomy for excision of ovarian cysts in patients with moderate or severe endometriosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

Endoscopic versus laparotomy management of endometriomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

Presacral neurectomy for the treatment of pelvic pain associated with endometriosis: a controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

Variations in the use of medical and surgical services by the Medicare population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

Systematic reviews: synthesis of best evidence for clinical decisions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

Chronic pelvic pain and previous sexual abuse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

A comparative study of women with chronic pelvic pain, chronic nonpelvic pain and those with no history of pain attending general practitioners

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

The Maine Women's Health Study: I. Outcomes of hysterectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

Patient satisfaction with results of hysterectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

Placebo-controlled study on serum concentrations of CA-125 before and after treatment of endometriosis with danazol or high-dose medroxyprogesterone acetate alone or after surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

7 January 2021

Ovarian suppression induced with Buserelin or danazol in the management of endometriosis: a randomized, comparative study

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

7 January 2021

Comparison of cyproterone acetate and danazol in the treatment of pelvic pain associated with endometriosis

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

7 January 2021

Prospective, randomized, double-blind, controlled trial of laser laparoscopy in the treatment of pelvic pain associated with minimal, mild, and moderate endometriosis

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

7 January 2021

Incidence of symptom recurrence after hysterectomy for endometriosis

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904216-4

7 January 2021

10.1016/S0015-0282(02)04216-4

Identifiers

DOI

1 reference

5 August 2017

1 reference